Direct inhibition of MEK circumvents this problem, as it directly prevents ERK1/2 activation, and thus the application of MEK1/2 inhibitors such as selumetinib (AZD6244) and trametinib (GSK1120212) is pursued for melanoma treatment as well [11, 12]. Here, MAPK3 is linked to melanoma.